Testing effectiveness (Phase 2)Active Not RecruitingNCT06480565What this trial is testingA Phase 1/2 Trial of ADI-270 in ccRCCWho this might be right forClear Cell Renal Cell Carcinoma Adicet Therapeutics 60
Early research (Phase 1)Ended earlyNCT05909995What this trial is testingInterventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsWho this might be right forMelanomaHepatocellular Carcinoma (HCC)Renal Cell Carcinoma (RCC)+3 more Incyte Corporation 8
Large-scale testing (Phase 3)Study completedNCT02829775What this trial is testingContinued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical StudiesWho this might be right forChronic Myelogenous LeukemiaMalignant MelanomaRenal Cell Carcinoma Hoffmann-La Roche 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT07047001What this trial is testingVorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell CarcinomaWho this might be right forRenal Cell Carcinoma (RCC)Adjuvant Dong Wen 60
Testing effectiveness (Phase 2)Study completedNCT00609934What this trial is testingStudy of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the BoneWho this might be right forRenal Cell Carcinoma University Health Network, Toronto 12
Not applicableStudy completedNCT00005799What this trial is testingFludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+42 more Fred Hutchinson Cancer Center 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07218692What this trial is testingRP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on ImmunotherapyWho this might be right forAdvanced Clear Cell Renal Cell CarcinomaAdvanced Renal Cell CarcinomaAdvanced Sarcomatoid Renal Cell Carcinoma+6 more City of Hope Medical Center 35
Not applicableActive Not RecruitingNCT03291028What this trial is testingAnalysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial CarcinomaWho this might be right forRenal Cell CarcinomaUrothelial CarcinomaBladder Cancer+2 more Fox Chase Cancer Center 15
Early research (Phase 1)Study completedNCT02077933What this trial is testingStudy of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic TumorsWho this might be right forNeoplasmsBreast NeoplasmsKidney Neoplasms+1 more Novartis Pharmaceuticals 79
Testing effectiveness (Phase 2)Study completedNCT00719264What this trial is testingSafety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney CancerWho this might be right forCarcinomaAdenocarcinomaRenal Cell+2 more Novartis Pharmaceuticals 365
Not applicableLooking for participantsNCT03747133What this trial is testingSABR for Renal TumorsWho this might be right forRenal Tumor University Health Network, Toronto 90
Testing effectiveness (Phase 2)Study completedNCT00502307What this trial is testingTivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell CarcinomaWho this might be right forCarcinoma, Renal Cell AVEO Pharmaceuticals, Inc. 272
Testing effectiveness (Phase 2)Looking for participantsNCT05824975What this trial is testingEvaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)Who this might be right forAdvanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more GI Innovation, Inc. 358
Testing effectiveness (Phase 2)Looking for participantsNCT05086692What this trial is testingA Beta-only IL-2 ImmunoTherapY StudyWho this might be right forAdvanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more Medicenna Therapeutics, Inc. 115
Early research (Phase 1)Active Not RecruitingNCT05238883What this trial is testingHFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid TumorsWho this might be right forGastric CancerRenal Cell CarcinomaMelanoma+6 more HiFiBiO Therapeutics 72
Testing effectiveness (Phase 2)Ended earlyNCT05714553What this trial is testingNUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursWho this might be right forAdvanced CancerAdvanced Solid TumorNeoplasm Malignant+14 more NuCana plc 19
Testing effectiveness (Phase 2)Ended earlyNCT03185182What this trial is testingDiagnostic Imaging for Clear Cell Renal Cell CarcinomaWho this might be right forClear Cell Renal Cell Carcinoma Region Skane 5
Early research (Phase 1)Ended earlyNCT04234113What this trial is testingStudy of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid TumorsWho this might be right forThyroid CancerRenal Cell CarcinomaNon Small Cell Lung Cancer+16 more SOTIO Biotech AG 115
Early research (Phase 1)Looking for participantsNCT05433142What this trial is testingStudy of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaWho this might be right forClear Cell Renal Cell Carcinoma Xencor, Inc. 307
Testing effectiveness (Phase 2)WithdrawnNCT03149159What this trial is testingInvestigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent NivolumabWho this might be right forClear Cell Renal Cell CarcinomaMetastatic Renal Cell Carcinoma Medical University of South Carolina